Imatinib Does Not Impair Specific Antitumor T-Cell Immunity in Patients With Chronic Myeloid Leukemia

Leukemia - United Kingdom
doi 10.1038/sj.leu.2404029
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Imatinib and Plasmacytoid Dendritic Cell Function in Patients With Chronic Myeloid Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2004English

Micro-Rna Response to Imatinib Mesylate in Patients With Chronic Myeloid Leukemia

Haematologica
Hematology
2010English

The BCL2L11 Deletion Polymorphism Is Not Associated With Imatinib Resistance in Chronic Myeloid Leukemia Patients: Meta Analysis

Oncotarget
Oncology
2017English

Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients

2012English

Gene Expression Signature of Primary Imatinib-Resistant Chronic Myeloid Leukemia Patients

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2006English

Pancreatic Enzyme Elevation in Chronic Myeloid Leukemia Patients Treated With Nilotinib After Imatinib Failure

Haematologica
Hematology
2009English

Treatment of Chronic Myeloid Leukemia With Generic Imatinib in Patients From Northeastern Part of India

International Journal of Research in Pharmaceutical Sciences
ToxicologyPharmaceuticsPharmacology
2019English

TKI-Related Platelet Dysfunction Does Not Correlate With Bleeding in Patients With Chronic Phase-Chronic Myeloid Leukemia With Complete Hematological Response

Clinical and Applied Thrombosis/Hemostasis
MedicineHematology
2019English

Prognostic Factors Associated With a Stable MR4.5 Achievement in Chronic Myeloid Leukemia Patients Treated With Imatinib

Oncotarget
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy